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Selected Interim Summary Data:
CMV-speciﬁc
T-cells (3x104CD3+/kg)
Control
Patient disposition
enrolled (withdrawn)
35 (18) 17 (6)
Reasons for withdrawal
GvHD or steroids at baseline 6 4
Insufﬁcient starting material 8 -
Other 4 2
New onset GvHD
post visit 2
3 (17.6%) 3 (27.3%)
Fold change from baseline
(peak) in CMV speciﬁc
cells (mean +/- SEM)a
109.1 +/- 42.5 10.5 +/- 7.1
Absolute change from
baseline (peak) in CMV
speciﬁc cells/ml
(mean +/- SEM)b
20870 +/- 6766 4867 +/- 2533
a p ¼ 0.017; b p¼ 0.056
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Introduction: Qualitative and quantitative deﬁciencies in
T-cell mediated immunity following allogeneic HSCT are
associated with a high incidence of cytomegalovirus (CMV)
infection, which remains amajor cause of morbidity and cost,
and a signiﬁcant indirect cause of mortality in this setting.
Adoptive cellular therapy (ACT) can potentially expedite
reconstitution of virus-speciﬁc immunity, minimizing the
period of risk. A number of phase I-II studies have demon-
strated proof of concept for such strategies, although
estimation of efﬁcacy is limited by potential selection bias.
We therefore conducted a randomized controlled trial to
evaluate immune reconstitution and safety of CMV-speciﬁc
T-cells (CMV-ASPECT: ClinicalTrials.gov NCT01220895).
Methods: The study enrolled CMV-seropositive patients
>16 yrs old, undergoing T-cell depleted (alemtuzumab)
HSCT from unrelated CMV-seropositive donors in 9 UK
centers. Patient and donor were required to share one or
more of the following HLA alleles: A*0101, A*0201, A*2402,
B*0702 or B*0801; and the donor to demonstrate >0.1%
HLA-streptamer positive CMV-speciﬁc T-cells. Randomiza-
tion was then performed 2:1 in favor of the treatment arm.
CMV-speciﬁc cells were directly selected from an aliquot
of the stem cell donation after streptamer-labeling. CMV
surveillance was performed using quantitative PCR. Patients
with Gd 2 aGvHD or systemic steroid administration at
baseline (D28) were withdrawn. CMV-speciﬁc T-cells were
administered pre-emptively for CMV DNAemia. Both groups
received best available antiviral pre-emptive treatment ac-
cording to standardized intervention criteria. Patients were
followed for immune reconstitution (primary endpoint) and
safety.
Results: From Oct 2010 to Jun 2013, 52 patients/donors were
enrolled. As of Sep 2013, all subjects had completed immune
assessments at 8 weeks post CMV detection and ﬁnal follow-
up visits were underway. The complete study safety and
immune reconstitution data will be analyzed January 2014.
Conclusions: In this ﬁrst randomized trial of CMV speciﬁc
T-cells post-HSCT, adoptive cell therapy (Cytovir CMV)
proved safe and resulted in earlier and greater durableexpansion of CMV-speciﬁc T cells and reconstitution of
immunity. Further investigation is warranted to determine if
the observed increase in CMV-speciﬁc cells translates to
clinical beneﬁt.43
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Adoptive immunotherapy is an effective strategy for the
treatment of EBV+ lymphoproliferative diseases (EBV-LPD)
arising after allogeneic hematopoietic stem cell (HSCT) or
solid organ transplant (SOT). This approach is often limited
by an inability to generate donor derived in vitro expanded
EBV-speciﬁc cytotoxic T-lymphocyte (EBV-CTL) lines in a
timely manner and/or donor derived EBV CTLs being
restricted by non-shared HLA alleles in the patient.
We have treated 28 consecutive patients for EBV LPD with
in vitro expanded EBV-CTLs derived from a donor other than
the patient or their transplant (HSCT or SOT) donor. EBV CTLs
were selected from a bank of 345 lines generated under GMP
conditions from normal donors. Patients were recipients of
unmodiﬁed (n¼7), T cell depleted (n¼7) or unrelated cord
blood (n¼7) HSCT or one (n¼5) or two (n¼2) SOTs. Patients
received infusions of 3rd party EBV-CTLs after failing a
median of 2 prior therapies including rituximab in all but one
case. Three patients failed prior infusions with EBV-CTLs
which were autologous (n¼1) or derived from their original
HSCT donor (n¼2). In these two patients it was demon-
strated that the donor derived EBV CTLs were restricted by a
non-shared HLA allele.
Third party EBV-CTLs were selected on the basis of HLA
matching at a minimum of 2/8 recipient alleles. When
known, EBV-CTLs restricted through HLA alleles present on
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infused.We evaluated HLA restriction in 20 of these lines and
inferred it in ﬁve. CTLs were restricted by a single HLA allele
(n¼12), by two alleles (n¼6) and less frequently by > than
two alleles (n¼2).
Patients received a median of 6 infusions most at 1x106
EBV-CTL/kg. Five patients received EBV-CTLs from >1 3rd
party donor. Infusions were associatedwithminimal toxicity.
Sixteen patients achieved CR, two patients PR and two SD.
Eight patients died of progressive disease, ﬁve shortly after
the ﬁrst infusion (17- 29 days). Response to EBV CTL therapy
correlated with HLA restriction but not the degree of HLA
matching. Radiographic and clinical responses correlated
with detectable increases in the frequency of CTL precursors
in the blood. However durable EBV CTL engraftment was not
seen.
This study demonstrates a high response rate among
patients with otherwise refractory EBV malignancy treated
with EBV speciﬁc 3rd party CTLs. EBV CTLs can be effective
when selected based on restriction to shared alleles despite
signiﬁcant HLA disparity. The bank of EBV speciﬁc T cells can
provide an immediate source of HLA partially matched
appropriately restricted T cells for adoptive immunotherapy
to treat EBV associated malignancy. This enables treatment
early in the course of disease and is anticipated to maximize
the response rate.44
Clinical Trial Evaluating DC/AML Fusion Cell Vaccination
in AML Patients Who Achieve a Chemotherapy-Induced
Remission
Jacalyn Rosenblatt 1, Richard M. Stone 2, Lynne Uhl 1,
Donna Neuberg 2, Baldev Vasir 2, Poorvi Somaiya 1,
Robin Joyce 1, James D. Levine 1, Vassiliki A. Boussiotis 1,
Jeffrey Zwicker 1, Jon E. Arnason 1, Katarina Luptakova 1,
David P. Steensma 2, Daniel J. DeAngelo 2, Ilene Galinsky 2,
Carol Delaney 1, Heidi Mills 1, Emma Breault 1,
Dina Stroopinsky 1, Donald Kufe 2, David Avigan 1. 1Beth Israel
Deaconess Medical Center, Boston, MA; 2Dana-Farber Cancer
Institute, Boston, MA
We have developed a promising leukemia vaccine in which
patient derived AML cells are fused with autologous
dendritic cells (DCs), presenting a broad array of antigens.
We are conducting a clinical trial in which AML patients
undergo vaccination with DC/AML fusion cells following
chemotherapy induced remission. Twenty-six patients un-
derwent collection of AML cells at disease presentation for
vaccine generation and immune monitoring studies.
Median age of the patients is 66 years. Tumor was collected
from either a bone marrow aspirate (N¼16), 20 cc of pe-
ripheral blood (N¼7), or leukapheresis product (N¼3) at
the time of presentation with newly diagnosed AML
(N¼25) or ﬁrst relapsed AML (N¼1). The mean yield of AML
cells was 109 x 106 cells with a mean viability of 91%.
Eligible patients achieving CR (N¼16) underwent leuka-
pheresis for DC generation. Adherent peripheral blood
mononuclear cells were cultured in the presence of GM-
CSF and IL-4 for 5-7 days, and exposed to TNFa for 48-72
hours to generate mature DCs. Fusion cells were generated
by co-culture of DCs with AML cells in the presence of 50%
polyethylene glycol and identiﬁed as cells co-expressing
antigens that were unique to the DC and tumor cells. Mean
fusion efﬁciency and viability was 38% and 85%, respec-
tively. Vaccination with DC/leukemia fusion cells was
initiated within 12 weeks from count recovery following
the ﬁnal cycle of chemotherapy. 13 patients received atleast two monthly vaccinations at a dose of 5x106 fusion
cells. 8 patients had intermediate risk cytogenetics, 3 pa-
tients had good risk cytogenetics, and 2 patients had a
complex karyotype. Vaccination was well tolerated, and
importantly, was not associated with clinically signiﬁcant
auto-immunity. Biopsy of vaccine site reactions demon-
strated a dense inﬁltrate of CD4 and CD8 T cells consistent
with recruitment of reactive T cell populations to the vac-
cine bed. To date, 9 patients remain in remission (69%),
with a mean follow up of 23 months. Peripheral blood
samples were collected prior to each vaccination and at 1,
3, and 6 months following completion of vaccination.
Vaccination resulted in the potent induction of leukemia
speciﬁc immunity as measured by an 8 fold increase (mean,
n¼6) in CD8 T cells expressing IFNg in response to ex vivo
exposure to autologous leukemia cell lysates. Bone marrow
derived T cells were isolated prior to and following vacci-
nation in patients who are HLA2.1+. Vaccination resulted in
the expansion of bone marrow inﬁltrating T cells recog-
nizing MUC1 (9 fold increase), WT1 (5 fold increase),
PRAME (12 fold increase) tumor antigens by tetramer
analysis (n¼2). In conclusion, DC/AML fusion cell vaccina-
tion results in the potent expansion of leukemia reactive
T cells and durable remissions following chemotherapy.
Enrollment to a second cohort in which patients receive
DC/AML fusion cell vaccination in combination with antI-
PD1 antibody is planned.GVH/GVL
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Chronic graft-versus-host disease (cGVHD) is the main cause
of late morbidity and non-relapse mortality after allogeneic
hematopoietic stem cell transplantation (AHSCT). T cells are
known modulators of cGVHD, while their in vivo kinetics, as
deﬁned by cell division, cell death and trafﬁcking, remain
largely uncharacterized, and current therapies for cGVHD
target T cell proliferation. T regulatory cells (T regs) are of
particular interest in cGVHD as adoptive transfer or in vivo
expansion of this cell type has resulted in amelioration of
cGVHD severity in pre-clinical models and in patients with
cGVHD. We have developed a method to measure T reg and
non-T reg cell kinetics using deuterated water labeling/
de-labeling combined with triple quadrupole GC/MS detec-
tion of deuteurium enrichment in DNA of dividing/dying
cells. Using a minor antigen mismatch murine model of
cGVHDwe show that in AHSCT recipients, donor CD4+ non-T
regs in the spleen have a proliferative advantage over T regs,
while in the syngeneic (genetically matched donor-recipient
pairs) control animals cell gain rates for these populations
are similar. The net result of the differential cell kinetics in
the cohort with cGVHD was fewer T regs in the spleens of
allogeneic versus syngeneic marrow recipients, with a
suggestion for decreased trafﬁcking out of the spleen. Eval-
uation of T reg and non-T reg CD4+ T cells within lymphoid
compartments (lymph nodes and peripheral blood) and
target organs (liver, intestines and skin) allowed assessment
